GLSI represents the Nasdaq listing for Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical firm centered on novel cancer immunotherapies. Its core objective is to help prevent breast cancer from returning in patients who have already had surgery. By targeting HER2/neu, a protein found in about 75% of breast cancers, the research targets a sizable group of patients, which explains why many investors track its developments.
Greenwich LifeSciences was founded in 2006 and maintains its headquarters in Stafford, Texas. It previously operated under the name Norwell, Inc. before adopting its current name in March 2018. The firm went public via IPO in September 2020 and lists on Nasdaq under the symbol GLSI.
Its lead candidate, GLSI-100, is an immunotherapy pairing GP2 — a nine-amino-acid peptide from the HER2/neu protein — with GM-CSF, an agent that stimulates the immune system. The aim is to prepare the patient's immune response to identify and target HER2/neu-expressing cells, thereby lowering the chance of recurrence after surgery.
This candidate is under evaluation in the FLAMINGO-01 Phase III trial, which examines safety and effectiveness in HER2-positive breast cancer patients. The company secured worldwide rights to the GP2 technology via a license from the Henry M. Jackson Foundation, with associated milestone and royalty commitments.
Operating as a clinical-stage biopharmaceutical entity, Greenwich LifeSciences has no approved products and reports no significant revenue. Its approach centers on progressing candidates through trials, obtaining approvals, and eventually commercializing or partnering therapies. Operations are funded mainly through equity raises, resulting in ongoing losses typical for this stage of drug development. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Attention around GLSI stems from the potential of its immunotherapy approach. Breast cancer ranks among the most prevalent cancers globally, and HER2/neu expression covers a broad portion of cases. Positive confirmation from FLAMINGO-01 could position GLSI-100 to meet a notable need for patients facing recurrence risk after standard care.
Prior Phase IIb findings sparked interest, showing no recurrences over a median five-year period in a subset of fully immunized patients, although small-study results warrant caution until validated in the larger Phase III effort. The platform may also extend to other HER2/neu-expressing cancers, offering additional avenues beyond breast cancer.
Key aspects of its profile include a compact, asset-light structure with a focused team and single main program, which supports efficient resource use yet heightens concentration risk. Valuation for this pre-revenue firm hinges largely on clinical milestones, regulatory updates, and financing activity rather than traditional financial metrics.
Those reviewing GLSI should account for several notable risks:
In my research process, Tickeron's AI Screener has proven helpful for identifying stocks in the biotech sector based on various criteria. It allows screening with technical indicators, fundamentals, AI signals, and customizable filters, which can be useful when evaluating companies like this one.
Greenwich LifeSciences holds a focused position as a clinical-stage biopharmaceutical company advancing an immunotherapy aimed at preventing breast cancer recurrence, an area with clear medical and potential commercial relevance. Its pipeline, highlighted by GLSI-100 in Phase III, along with possible extensions to other HER2/neu cancers, positions it as one worth monitoring. At the same time, its pre-revenue profile, concentrated asset base, and reliance on clinical and regulatory outcomes introduce meaningful uncertainty, framing it as a high-risk opportunity suited to a longer-term biotechnology investment horizon.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
GLSI broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 35 of the 40 cases the stock fell afterwards. This puts the odds of success at 88%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for GLSI crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for GLSI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on GLSI as a result. In 77 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for GLSI just turned positive on November 17, 2026. Looking at past instances where GLSI's MACD turned positive, the stock continued to rise in 42 of 45 cases over the following month. The odds of a continued upward trend are 90%.
GLSI moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +49.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where GLSI advanced for three days, in 213 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. GLSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GLSI's P/B Ratio (71.438) is slightly higher than the industry average of (3.596). P/E Ratio (-9.541) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology